JB Chemicals & Pharmaceuticals is currently trading at Rs. 1820.70, up by 37.15 points or 2.08% from its previous closing of Rs. 1783.55 on the BSE.
The scrip opened at Rs. 1794.60 and has touched a high and low of Rs. 1829.30 and Rs. 1766.65 respectively. So far 3154 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1984.75 on 28-Sep-2021 and a 52 week low of Rs. 980.85 on 03-Feb-2021.
Last one week high and low of the scrip stood at Rs. 1829.30 and Rs. 1674.60 respectively. The current market cap of the company is Rs. 14075.77 crore.
The promoters holding in the company stood at 54.00%, while Institutions and Non-Institutions held 25.38% and 20.62% respectively.
JB Chemicals & Pharmaceuticals has completed the acquisition of a portfolio of brands for the India market from Sanzyme (Sanzyme), a leading player in the probiotics and reproductive health segment in the country. The company has acquired portfolio of brands, for use and commercialization within India.The acquisition will mark company’s entry into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market with attractive set of brands.
JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: